Valbiotis (ALVAL.PA) Stock Price
Valbiotis Price
Over the last 10 years Valbiotis grew revenue by 56.9% annually, reaching 905,000.00 EUR. For Valbiotis, the net margin of -1,040.6% is up versus -2,913.1% a few years ago. The consensus 12-month price target for Valbiotis is 2.14 EUR, about 257.0% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
Valbiotis stock price
Valbiotis business model & stock analysis
Frequently asked questions about Valbiotis
Valbiotis SA is a biotechnology company focused on developing innovative solutions for preventing and managing metabolic diseases. Their business model revolves around the research, development, and commercialization of health solutions based on natural plant extracts. Valbiotis SA aims to address unmet medical needs through scientific expertise, strong partnerships, and an extensive portfolio of patented products. By leveraging their deep knowledge of metabolic disorders and targeting key markets, Valbiotis SA strives to provide effective and safe therapies to improve health outcomes for individuals suffering from metabolic diseases.
Valbiotis SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Valbiotis SA in the market include companies such as Amarin Corporation, Provention Bio Inc., and Sanofi SA.
Valbiotis SA is a French company specializing in the scientific research and development of innovative solutions for preventing and combating metabolic diseases. Founded in 2014, Valbiotis focuses on the discovery of therapeutic products derived from natural plant-based substances. Their aim is to address prevalent health issues such as obesity, type 2 diabetes, and cardiovascular diseases. With a dedicated team of experts and a rigorous approach to clinical trials, Valbiotis is committed to revolutionizing healthcare by offering safe, effective, and accessible solutions. Through continuous innovation and strategic partnerships, Valbiotis SA is poised to make a significant impact in the field of metabolic disorders.
Valbiotis SA has achieved several significant milestones throughout its journey. One noteworthy accomplishment for Valbiotis SA is the development and launch of its flagship product TOTUM-63. This innovative product targets metabolic diseases and has shown promising results in clinical trials. Additionally, Valbiotis SA has successfully formed strategic partnerships with renowned pharmaceutical companies, enhancing its reach and potential for future growth. Another achievement for the company is its listing on the Euronext Growth Paris stock exchange, which further solidifies its presence in the market. Valbiotis SA's continuous dedication to research, development, and market expansion shapes a promising future for the company.
Valbiotis SA is primarily present in France.
Valbiotis SA represents the values of innovation, scientific rigor, and sustainability. The company is dedicated to developing scientifically validated solutions for preventing and managing metabolic diseases. Valbiotis SA's corporate philosophy promotes a patient-centric approach, aiming to improve their quality of life and provide them with effective and safe health solutions. With a focus on research and collaboration, Valbiotis SA aims to tackle major global health challenges and contribute to the well-being of individuals affected by metabolic disorders. Through its commitment to excellence and ethical practices, Valbiotis SA strives to make a positive impact on the healthcare industry.
Analysts currently set an average price target of 2.18 EUR for the Valbiotis stock (median: 2.14 EUR), implying +262.7 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Valbiotis stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Valbiotis to generate revenue of 3.10 M EUR and earnings per share of -0.23 EUR.
The Valbiotis share (ALVAL.PA) is listed on 4 stock exchanges, including: Frankfurt (8JD.F), München (8JD.MU), Paris (ALVAL.PA).
Valbiotis SA is a French biotech company specializing in the development of innovative solutions for treating metabolic diseases. The business model is based on selling patented products and collaborating with leading companies in the food and pharmaceutical industries. The company focuses on developing drugs and products for treating diabetes, obesity, cholesterol, triglycerides, and non-alcoholic steatohepatitis (NASH). Valbiotis works closely with the food industry to develop dietary solutions. The company has received awards and has partnerships with European universities and research institutions. Overall, Valbiotis SA aims to improve the health and well-being of patients with metabolic diseases through innovation and is a pioneer in a new era of treatment methods.
The expected revenue of Valbiotis is 3.10 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Valbiotis is -5.45 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Valbiotis is currently -2.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Valbiotis stock.
The price-to-sales ratio (P/S) of Valbiotis is currently 4.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Valbiotis stock.
The Eulerpool Quality Score for Valbiotis is 3/10.
The ISIN of Valbiotis is FR0013254851. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Valbiotis is A2DS5F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Valbiotis is ALVAL.PA. The ticker symbol is used to trade Valbiotis shares on the stock exchange.
Valbiotis stock
Valbiotis Peer Group
Valbiotis Ticker
Valbiotis FIGI
All fundamentals and in-depth analysis of Valbiotis
Our stock analysis for Valbiotis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Valbiotis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.